INDICATIONS AND USAGE:

Thyroid Cancer CABOXEN is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). 

DOSAGE AND ADMINISTRATION The recommended daily dose of Cabozantinib is 140 mg (one 80-mg and three 20-mg capsules). Do not administer Cabozantinib with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking Cabozantinib. Continue treatment until disease progression or unacceptable toxicity occurs. Do NOT substitute Cabozantinib capsules with Cabozantinib tablets. Swallow Cabozantinib capsules whole. Do not open Cabozantinib capsules. Do not take a missed dose within 12 hours of the next dose. Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking Cabozantinib. In Patients with Hepatic Impairment: The recommended starting dose of Cabozantinib for patients with mild to moderate hepatic impairment is 80 mg.

FIND A PRODUCT